CiRA starts service offering HLA-typed iPS cell stocks, Dainippon Sumitomo first customer

Kyoto University’s CiRA has initiated a service based on human leukocyte-antigen (HLA)-typed iPS cell stocks. Appropriate HLA-types in tissue transplantation greatly reduces the risk of rejection. This time, CiRA has offered to Dainippon Sumitomo and its Helios joint venture to prepare HLA-typed retinal pigment epithelial cells (RPE cells) for clinical trials with appropriate patients, to be started in 2017.

CiRA website, Nikkei Biotech news release August 6, 2015

Most popular posts:

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny